Otonomy to Report Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update
24 févr. 2017 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 24, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Holds Investor and Analyst Day and Provides Corporate Update
07 oct. 2016 08h00 HE
|
Otonomy, Inc.
SAN DIEGO, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Completes Enrollment in OTIPRIO(TM) Phase 2 Trial and Demonstrates Clinical Feasibility in Patients With Acute Otitis Externa
01 déc. 2015 07h00 HE
|
Otonomy, Inc.
SAN DIEGO, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere's Disease
18 nov. 2015 07h00 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Present Results for AuriPro(TM) Phase 3 and OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
24 sept. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Appoints Ted Schroeder to Board of Directors
01 sept. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Initiates Phase 2 Clinical Trial for AuriPro(TM) in Second Label Expansion Indication
28 juil. 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, July 28, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Phase 2b Topline Data for OTO-104 in Meniere's Disease
21 mai 2015 16h05 HE
|
Otonomy, Inc.
Narrowly missed primary endpoint of reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period, p = 0.067
Achieved statistical significance on...
Otonomy Appoints Eric Loumeau as General Counsel and Chief Compliance Officer
18 mai 2015 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports First Quarter 2015 Financial Results and Provides Corporate Update
12 mai 2015 16h01 HE
|
Otonomy, Inc.
SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...